AbbVie Aims For $1 Billion Sales In Japan By 2020
This article was originally published in PharmAsia News
Gary M. Winer, the president and CEO of the Japanese subsidiary of the newly formed AbbVie G.K. with headquarters in Tokyo, said in a Mixonline interview the company aims to increase its domestic sales from the current $616 million to $1 billion by 2020.
You may also be interested in...
Pierre Bourdage, global head of biopharmaceuticals at Sandoz, has hit back at false statements and misleading claims around biosimilars that persist despite mounting evidence to the contrary.
A recent Spanish self-care and cosmetics industry conference organized by ANEFP and Beauty Cluster explores the commercial opportunity in China via online marketplace Tmall.
Australia’s NeuClone expects to be among the first biosimilar market entrants to challenge Stelara, with the firm’s NeuLara ustekinumab rival reporting positive Phase I data as the company prepares to move ahead with Phase III trials next year.